PDL BioPharma (PDLI) Stock Price, News & Analysis

Company Overview

PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Key Stats

• Today's Range: $2.47 to $2.47
• 50-Day Range: $2.47 to $2.47
• 52-Week Range: $2.09 to $3.86
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PDLI Stock Analysis - Frequently Asked Questions

How were PDL BioPharma's earnings last quarter?

PDL BioPharma, Inc. (NASDAQ:PDLI) issued its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by $0.53. The biotechnology company earned $5.21 million during the quarter.

What other stocks do shareholders of PDL BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PDL BioPharma investors own include AT&T (T), OPKO Health (OPK), Advanced Micro Devices (AMD), Canopy Growth (CGC), Novavax (NVAX), Pfizer (PFE) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 8/06/2020
• Today: 6/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PDLI
• CIK: 882104
• Web: www.pdl.com
• Phone: 775-832-8500
• Fax: 775-832-8501
• Employees: 109
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A